| Aug 27 |
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
|
| Aug 15 |
After Plunging -15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Clearside Biomedical (CLSD)
|
| Aug 12 |
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 12 |
Clearside Biomedical GAAP EPS of -$0.10 beats by $0.04, revenue of $0.09M misses by $0.04M
|
| Aug 12 |
Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Aug 11 |
Clearside Biomedical Q2 2024 Earnings Preview
|
| Aug 8 |
Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
|
| Aug 5 |
Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
| Aug 1 |
Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
|
| Jul 29 |
Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in China
|
